Hepatitis C Virus Transmission through Quarantine Fresh-frozen Plasma

Summary

In 1994, quarantine fresh-frozen plasma (Q-FFP) was introduced in Germany in order to reduce the risk of HIV and HCV transmission. In 1998, an acute HCV infection of a patient was reported to us. The lookback revealed that this patient had received two Q-FFP from a donor who had seroconverted for HCV in the meantime. Recipients of further plasma donations from this donor were identified. Back-up specimens of these donations were investigated in several laboratories. A total of 25 additional HCV-PCR positive plasma units had been transfused to 12 further patients. HCV infections were diagnosed in seven of these recipients, three patients had already been deceased. One of the remaining two recipients was already HCV positive prior to transfusion, in the other patient, no HCV infection was detectable. This patient had received three units of an “early” plasma donation , which was tested negative by PCR in one laboratory, but positive in the other. The subsequent, clinically infectious donation had the same discrepant PCR results. Thus, eight cases of HCV transmission were revealed and classified as “certain” with regard to causality, also due to an identical HCV genotype, i.e. 3e. Some of these infections would have been prevented by application of a different anti-HCV assay. The assay used in the respective plasmapheresis station was in-sensitive in this individual case for more than 400 days after the first PCR positive donation. This caused the release of the above mentioned infectious units. Upon re-testing the backups, three of four other anti-HCV assays revealed a positive result already 104 days after the first PCR-positive donation. The donor had increased ALAT levels (> 23 IU/L) at nine of 28 donations, two of these were higher than 2.5 times the upper normal limit, and two were higher than 68 IU/L, which is the cut-off value for male blood donors in Germany. The results of these (look-back) studies arouse several queries, i.e. differences in the diagnostic sensitivity between current anti-HCV and PCR tests, the accuracy of risk-estimates (especially when based on hemovigilance studies for Q-FFP), the value of ALAT testing, and currently practised release algorithms for Q-FFP.

Key words

Hepatitis C - PCR - plasmapheresis - quarantine fresh-frozen plasma

• References

• 1 Contreras M, Ala FA, Greaves M, Jones J, Levin M, Machin SJ, Morgan C, Murphy W, Napier JAF, Thomson AR. Guidelines for the use of fresh frozen plasma. Transfus Med 1992; 02: 57-63.
• 2 Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 1994; 271: 777-81.
• 3 Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996; 84: 732-47.
• 4 Baglin T. Management of warfarin (coumarin) overdose. Blood Rev 1998; 12: 91-8.
• 5 Institut für Gesundheits-System-Forschung Kiel, WHO Collaborating Centre for Public Health Research. Report on the Symposium Pharmaceuticals of Blood and Plasma: Self-sufficiency and Safety – Analysis and Perspectives – Bonn. March 16, 1994. 1994. GSF Schriftenreihe, Bd; 45.
• 6 Wallace EL, Churchill WH, Surgenor DM, Cho GS, McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998; 38: 625-36.
• 7 Glück D, Kubanek B, Maurer C, Petersen N. Seroconversion of HIV, HCV, and HBV in blood donors in 1996 risk of virus transmission by blood products in Germany. Infusionsther Transfusionsmed 1998; 25: 82-4.
• 8 AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127: 904-9.
• 9 Bianco C. Choice of human plasma preparations for transfusion. Transfus Med Rev 1999; 13: 84-88.
• 10 Lelie PN, Cuypers HT, Reesink HW, van der Poel CL, Winkel I, Bakker E, van Exel-Oehlers PJ, Vallari D, Allain JP, Mimms L. Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays. J Med Virol 1992; 37: 203-9.
• 11 Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del-Valle OM, Rodes J, Ordinas A. Persistent hepatitis C viremia after acute selflimiting posttransfusion hepatitis C. Hepatology 1995; 21: 639-44.
• 12 Esteban JI, Gomez J, Martell M, Cabot B, Quer J, Camps J, Gonzalez A, Otero T, Moya A, Esteban R, Guardia J. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996; 334: 555-60.
• 13 Maple PA, McKee T, Desselberger U, Wreghitt TG. Hepatitis C virus infections in transplant patients: serological and virological investigations. J Med Virol 1994; 44: 43-8.
• 14 Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212-20.
• 15 Beld M, Penning M, van Putten M, van den Hoek A, Damen M, Klein MR, Goudsmit J. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94: 1183-91.
• 16 Lefrere JJ, Guiramand S, Lefrere F, Mariotti M, Aumont P, Lerable J, Petit JC, Girot R, Morand JL. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997; 175: 316-22.
• 17 Beld M, Penning M, van Putten M, Lukashov V, van den Hoek A, McMorrow M, Goudsmit J. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. Hepatology 1999; 29: 1288-98.
• 18 Legler TJ, Köhler M, Heermann K-H. High-throughput extraction, amplification, and detection (HEAD) of HCV-RNA in individual blood donations. J Clin Virol 1999; 13: 95-103.
• 19 Richtlinie für die Überwachung der Herstellung und des Verkehrs mit Blutzubereitungen. Bundesgesundhbl 1997; 02: 58-67.
• 20 Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz TFG). Bundesgesetzblatt. 1998 Teil I Nr. 42:1752-60.
• 21 Graul A, Keller-Stanislawski B. Hämovigilanz von Blutkomponenten. Meldungen an das Paul-Ehrlich-Institut vom 1.1.1995 bis zum 15.11.1998. Bundesgesundhbl 1999; 42: 143-9.
• 22 Mitteilungen der Arbeitskreises Blut beim Robert-Koch-Institut. Bundesgesundhbl 1994; 12: 512-5.
• 23 Burgin M, Hopkins G, Moore B, Nasser J, Richardson A, Minchinton R. Serum IgG and IgM levels in new and regular long-term plasmapheresis donors. Med Lab Sci 1992; 49: 265-70.
• 24 Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion 1995; 35: 903-10.
• 25 Nübling CM, Willkommen H, Löwer J. Hepatitis C transmission associated with intravenous immunoglobulins [letter]. Lancet 1995; 345: 1174.